A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy
Background Non-proliferative and proliferative diabetic retinopathy are common complications of diabetes and a major cause of sight loss. Anti-vascular endothelial growth factor drugs represent a treatment option for people with diabetic retinopathy and are routinely used to treat various other eye...
Saved in:
Main Authors: | Robert Hodgson, Matthew Walton, Helen Fulbright, Laura Bojke, Ruth Walker, Alexis Llewellyn, Sofia Dias, Lesley Stewart, David Steel, John Lawrenson, Tunde Peto, Mark Simmonds |
---|---|
Format: | Article |
Language: | English |
Published: |
NIHR Journals Library
2025-01-01
|
Series: | Health Technology Assessment |
Subjects: | |
Online Access: | https://doi.org/10.3310/NHYK3694 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series
by: Anil Babanrao Gangwe, et al.
Published: (2025-01-01) -
THE ROLE OF ANTI-VEGF THERAPY IN IMPROVING THE EFFICACY OF SURGICAL TREATMENT OF SECONDARY NEOVASCULAR GLAUCOMA
by: Uliana Sydorchuk, et al.
Published: (2024-10-01) -
Relationship between VEGF to PEDF ratio and in-hospital mortality in acute respiratory distress syndrome patients
by: Qifeng Luo, et al.
Published: (2025-01-01) -
Innovator ranibizumab ComparEd to Biosimilar ranibizumab in combination with Expansile gas in submaculaR HemorrhaGe: the ICEBERG study
by: Debdulal Chakraborty, et al.
Published: (2025-01-01) -
Effectiveness of treatment for different stages of diabetic retinopathy in type 2 diabetes
by: A.V. Serdiuk, et al.
Published: (2024-11-01)